KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antoni Ribas(University of California, Los Angeles), Jacob Schachter, Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Razi Ghori(Merck & Co., Inc., Rahway, NJ, USA (United States)), Inge Marie Svane(Copenhagen University Hospital), Rosalie Stephens(Auckland City Hospital), Félix Couture, Henrik Schmidt(University of Southern Denmark), Georgina V. Long(The University of Sydney), Gil Bar‐Sela(Emek Medical Center), Paola Queirolo, Michal Lotem(Hadassah Medical Center), Blanca Homet Moreno(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bijoyesh Mookerjee(Novartis (United States)), Anna Maria Di Giacomo(University of Siena), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Victoria Atkinson(Greenslopes Private Hospital), Pier Francesco Ferrucci(MultiMedica)
Cited by 50
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k